SGO Winter Meeting | Conference

PARP Combinations Offer New Opportunities in Ovarian Cancer

February 11th 2018

PARP inhibitor combination regimens have the potential to enhance the relatively modest benefit offered by several monotherapy approaches used for the treatment of patients with ovarian cancer.

Dr. Backes on Pelvic Exenteration Surgery in Gynecologic Cancer

February 10th 2018

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses pelvic exenteration surgery for patients with gynecologic cancer.

Dr. Arend on the Rationale of Novel Combinations in Gynecologic Cancer

February 10th 2018

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the rationale behind novel combination strategies for patients with gynecologic cancer.

PARP Combos With Bevacizumab, Immunotherapy in Development for Ovarian Cancer Treatment

February 10th 2018

Rebecca C. Arend, MD, discussed novel combinations being investigated for the treatment of patients with ovarian cancer.

Expert Highlights PARP Inhibitor Advancements in Ovarian Cancer, Points to Future Combos

February 10th 2018

David O'Malley, MD, discusses the excitement surrounding PARP inhibitors for patients with ovarian cancer.

Immune Checkpoint Combinations Show Promise in Endometrioid Disease

February 10th 2018

Many endometrioid cancers express high RNA levels for multiple immune checkpoints, and this may allow physicians to treat these patients with combination immune therapies.

Dr. Moore on Immunotherapy and PARP Combinations in BRCA-Mutated Ovarian Cancer

February 10th 2018

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses combinations of immunotherapy with PARP inhibitors for patients with BRCA-mutated ovarian cancer.

Dr. West on Quality of Life Challenges in Gynecologic Cancer

February 10th 2018

Lindsay West, MD, gynecologic oncologist, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, discusses the challenges with quality of life for patients with gynecologic cancer.

Adjuvant Therapy Does Not Improve Survival for Early Stage Uterine Leiomyosarcoma

February 9th 2018

Adjuvant therapy, regardless of the treatment modality, did not improve overall survival compared with observation for women with early stage, uterine-confined leiomyosarcoma.

Robotic Radiosurgery May Provide New Option for Recurrent Gynecologic Cancers

February 9th 2018

The administration of stereotactic body radiation therapy through the use of CyberKnife therapy appears to be a safe and effective salvage treatment for women with previously irradiated, locally recurrent gynecologic cancer.

Immunotherapy Combinations Slated to Pave the Way in Ovarian Cancer Treatment

February 9th 2018

Kathleen Moore, MD, discusses combination strategies with immunotherapy for patients with ovarian cancer.

Study Highlights Impact of Race, Geography on Genetic Variation in Endometrial Cancer

February 9th 2018

An analysis of black women of Caribbean descent with type I or type II endometrial cancer showed that this population expressed significant differences in genetic variations compared with a nationwide population of patients with endometrial cancer.

Dr. Al-Niaimi on the Future Role of Cytoreductive Surgery in Ovarian Cancer

February 9th 2018

Ahmed N. Al-Niaimi, MD, assistant professor of obstetrics and gynecology, University of Wisconsin School of Medicine and Public Health, discusses the future role for cytoreductive surgery for the treatment of patients with ovarian cancer.

Dr. Crane on the Impact of PARP Inhibitors in Ovarian Cancer

February 9th 2018

Erin K. Crane, MD, MPH, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the impact of PARP inhibitors for patients with ovarian cancer.